Lobbying

Hackensack Meridian Health's latest lobbying report covers Q2 2026, at $340K. The four quarters Q3 2025–Q2 2026 total $1.4M. Its first report covers Q3 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Hackensack Meridian Health

Latest quarter
$340K
Q2 2026 · 4 reports
Last 12 months
$1.4M
Last 4 quarters
vs last quarter
0.0%
Q2 2026 against the quarter before
First report
Q3 2022
The first quarter a report named it

Lobbying by quarter

Hackensack Meridian Health lobbying by quarter
Hackensack Meridian Health lobbying by quarter
QuarterAmountReports
Q3 2022$37K1
Q4 2022$297K5
Q1 2023$297K5
Q2 2023$297K5
Q3 2023$297K5
Q4 2023$317K5
Q1 2024$277K6
Q2 2024$327K5
Q3 2024$317K5
Q4 2024$317K5
Q1 2025$357K6
Q2 2025$340K6
Q3 2025$340K4
Q4 2025$340K4
Q1 2026$340K4
Q2 2026$340K4

Policy issues the reports name

  • Health issues54 reports
  • Medicare and Medicaid50 reports
  • Budget and appropriations27 reports
  • Education12 reports
  • Medical research and clinical labs9 reports
  • Science and technology6 reports
  • Pharmacy2 reports
  • Taxation1 reports
  • Immigration1 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES62 reports
  • SENATE61 reports
  • Centers For Medicare and Medicaid Services (CMS)29 reports
  • Health & Human Services, Dept of (HHS)13 reports
  • White House Office11 reports
  • Health Resources & Services Administration (HRSA)9 reports
  • Natl Institutes of Health (NIH)3 reports
  • Office of Science & Technology Policy (OSTP)3 reports
  • Federal Emergency Management Agency (FEMA)2 reports
  • Office of Natl Drug Control Policy (NDCP)1 reports

Firms it paid

Firm
In-houseHackensack Meridian Health$2.6M15 quarters
Impact Health Policy Partners$660K15 quarters
DB3$560K10 quarters
Strategic Health Care$407K12 quarters
Baker Donelson Bearman Caldwell & Berkowitz$300K6 quarters
Welsh Rose$280K6 quarters
Hooper, Lundy & Bookman, P.C.$30K11 quarters

Former officials lobbying for it

Former position
THOMAS DASCHLEFormer United States SenatorQ2 2023

Lobbying reports

Filed by
07/20for Q2DB3$60K
07/08for Q2Welsh Rose$50K
07/07for Q2In-house$180K
07/06for Q2Impact Health Policy Partners$50K
04/20for Q1DB3$60K
04/10for Q1Impact Health Policy Partners$50K
04/08for Q1Welsh Rose$50K
04/08for Q1In-house$180K
01/20for Q4 2025DB3$60K
01/16for Q4 2025Welsh Rose$50K
01/13for Q4 2025Impact Health Policy Partners$50K
01/06for Q4 2025In-house$180K
25/10/20for Q3 2025DB3$60K
25/10/20for Q3 2025Welsh Rose$50K
25/10/13for Q3 2025Impact Health Policy Partners$50K
25/10/10for Q3 2025In-house$180K
25/07/18for Q2 2025Hooper, Lundy & Bookman, P.C.Under $5,000
25/07/18for Q2 2025DB3$60K
25/07/16for Q2 2025Impact Health Policy Partners$50K
25/07/10for Q2 2025Strategic Health CareUnder $5,000